SRSF3-Mediated Ki67 Exon 7-Inclusion Promotes Head and Neck Squamous Cell Carcinoma Progression via Repressing AKR1C2
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24043872 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Miaomiao Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST) & Key Laboratory of Oral Biomedicine Ministry of Education, Schoo…. Hauptthemen laut MEDLINE: Cell Transformation, Neoplastic, Head and Neck Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, the Key Research and Development Program of Hubei Province, Natural Science Foundation of China.
Abstract (Originalsprache)
Ki67 is a well-known proliferation marker with a large size of around 350 kDa, but its biological function remains largely unknown. The roles of Ki67 in tumor prognosis are still controversial. Ki67 has two isoforms generated by alternative splicing of exon 7. The roles and regulatory mechanisms of Ki67 isoforms in tumor progression are not clear. In the present study, we surprisingly find that the increased inclusion of Ki67 exon 7, not total Ki67 expression level, was significantly associated with poor prognosis in multiple cancer types, including head and neck squamous cell carcinoma (HNSCC). Importantly, the Ki67 exon 7-included isoform is required for HNSCC cell proliferation, cell cycle progression, cell migration, and tumorigenesis. Unexpectedly, Ki67 exon 7-included isoform is positively associated with intracellular reactive oxygen species (ROS) level. Mechanically, splicing factor SRSF3 could promote exon 7 inclusion via its two exonic splicing enhancers. RNA-seq revealed that aldo-keto reductase AKR1C2 is a novel tumor-suppressive gene targeted by Ki67 exon 7-included isoform in HNSCC cells. Our study illuminates that the inclusion of Ki67 exon 7 has important prognostic value in cancers and is essential for tumorigenesis. Our study also suggested a new SRSF3/Ki67/AKR1C2 regulatory axis during HNSCC tumor progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST) & Key Laboratory of Oral Biomedicine Ministry of Education, School & Hospital of Stomatology, Wuhan University, Wuhan 430079, China.
- RNA Institute, Wuhan University, Wuhan 430072, China.
- State Key Laboratory of Virology and Hubei Key Laboratory of Cell Homeostasis, College of Life Science, TaiKang Center for Life and Medical Sciences, Wuhan University, Wuhan 430072, China.
- Department of Oral and Maxillofacial Surgery, School & Hospital of Stomatology, Wuhan University, Wuhan 430079, China.
- Department of Endodontics, School & Hospital of Stomatology, Wuhan University, Wuhan 430079, China.
Förderung
- National Natural Science Foundation of China
- the Key Research and Development Program of Hubei Province
- Natural Science Foundation of China
- Key Research and Development Program of Hubei Province
Zitieren
APA
Liu, M., Lin, C., Huang, Q., Jia, J., Guo, J., & Jia, R. (2023). SRSF3-Mediated Ki67 Exon 7-Inclusion Promotes Head and Neck Squamous Cell Carcinoma Progression via Repressing AKR1C2. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24043872
Vancouver
Liu M, Lin C, Huang Q, Jia J, Guo J, Jia R. SRSF3-Mediated Ki67 Exon 7-Inclusion Promotes Head and Neck Squamous Cell Carcinoma Progression via Repressing AKR1C2. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24043872
BibTeX
@article{Liu2023,
author = {Liu, Miaomiao and Lin, Can and Huang, Qiwei and Jia, Jun and Guo, Jihua and Jia, Rong},
title = {SRSF3-Mediated Ki67 Exon 7-Inclusion Promotes Head and Neck Squamous Cell Carcinoma Progression via Repressing AKR1C2},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24043872}
}
EUVIMED